SK10395A3 - Polypeptide and its using - Google Patents

Polypeptide and its using Download PDF

Info

Publication number
SK10395A3
SK10395A3 SK103-95A SK10395A SK10395A3 SK 10395 A3 SK10395 A3 SK 10395A3 SK 10395 A SK10395 A SK 10395A SK 10395 A3 SK10395 A3 SK 10395A3
Authority
SK
Slovakia
Prior art keywords
cys
polypeptide
lys
ala
cells
Prior art date
Application number
SK103-95A
Other languages
English (en)
Slovak (sk)
Inventor
Robert A Volkmann
Nicholas A Saccomano
Douglas Phillips
Mary E Kelly
Original Assignee
Pfizer
Nps Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Nps Pharma Inc filed Critical Pfizer
Publication of SK10395A3 publication Critical patent/SK10395A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
    • C07K14/43518—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from spiders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Insects & Arthropods (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SK103-95A 1992-07-27 1993-06-10 Polypeptide and its using SK10395A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US91953892A 1992-07-27 1992-07-27
PCT/US1993/005392 WO1994002511A1 (en) 1992-07-27 1993-06-10 Calcium channel blocking polypeptide from agelenopsis aperta

Publications (1)

Publication Number Publication Date
SK10395A3 true SK10395A3 (en) 1995-06-07

Family

ID=25442279

Family Applications (1)

Application Number Title Priority Date Filing Date
SK103-95A SK10395A3 (en) 1992-07-27 1993-06-10 Polypeptide and its using

Country Status (28)

Country Link
US (1) US5599559A (hu)
EP (1) EP0656905B1 (hu)
JP (1) JP2571197B2 (hu)
KR (1) KR950702577A (hu)
CN (1) CN1086824A (hu)
AT (1) ATE157672T1 (hu)
AU (1) AU662066B2 (hu)
BR (1) BR9306796A (hu)
CA (1) CA2139947C (hu)
CZ (1) CZ281539B6 (hu)
DE (1) DE69313650T2 (hu)
DK (1) DK0656905T3 (hu)
ES (1) ES2105284T3 (hu)
FI (1) FI933349A (hu)
GR (1) GR3024637T3 (hu)
HR (1) HRP931050B1 (hu)
HU (1) HU213353B (hu)
IL (1) IL106424A0 (hu)
MX (1) MX9304497A (hu)
MY (1) MY131356A (hu)
NZ (1) NZ253611A (hu)
PL (1) PL307258A1 (hu)
RU (1) RU2104286C1 (hu)
SK (1) SK10395A3 (hu)
TW (1) TW271442B (hu)
WO (1) WO1994002511A1 (hu)
YU (1) YU51593A (hu)
ZA (1) ZA935370B (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6096514A (en) * 1988-04-04 2000-08-01 Sibia Neurosciences, Inc. Human calcium channel compositions and methods
CA1341170C (en) * 1988-04-04 2001-01-16 Steven B. Ellis Calcium channel compositions and methods
US5876958A (en) * 1988-04-04 1999-03-02 Sibia Neurosciences, Inc. Assays of cells expressing human calcium channels containing α1 β subunits
US20040018510A1 (en) 1990-11-08 2004-01-29 Merck & Co., Inc. Human calcium channel compositions and methods
US6653097B1 (en) 1991-08-15 2003-11-25 Merck & Co., Inc. Human calcium channel compositions and methods
US5407820A (en) * 1988-04-04 1995-04-18 The Salk Institute Biotechnology/Industrial Associates, Inc. Calcium channel α-2 subunit DNAs and cells expressing them
US6387696B1 (en) 1988-04-04 2002-05-14 Merck & Co., Inc. Human calcium channel compositions and methods
US5874236A (en) * 1988-04-04 1999-02-23 Sibia Neurosciences. Inc. DNA encoding human calcium channel α-1A, β1, β-2, and β-4 subunits, and assays using cells that express the subunits
US5846757A (en) * 1988-04-04 1998-12-08 Sibia Neurosciences, Inc. Human calcium channel α1, α2, and β subunits and assays using them
US6090623A (en) * 1993-08-11 2000-07-18 Merck & Co., Inc. Recombinant human calcium channel β4 subunits
ES2075796B1 (es) * 1993-08-17 1996-03-01 Pfizer Polipeptido de la agelenopsis aperta bloqueante de los canales de ca lcio
AU7142996A (en) 1995-09-29 1997-04-28 Universita' Degli Studi Di Siena Regulated genes and uses thereof
ATE306546T1 (de) 1996-08-23 2005-10-15 Ludwig Inst Cancer Res Rekombinanter vaskulärer endothelzellen wachstumsfaktor d (vegf-d)
US6528630B1 (en) 1997-12-03 2003-03-04 Merck & Co., Inc. Calcium channel compositions and methods
IL140665A0 (en) * 1998-07-10 2002-02-10 Novartis Ag Antihypersensitive combination of valsartan and calcium channel blocker
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
CN103768469A (zh) * 2012-10-23 2014-05-07 葛继云 一种治疗妇科炎症的中药组合物及其制备方法和用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US4925664A (en) * 1986-10-20 1990-05-15 University Of Utah Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5122596A (en) * 1989-09-29 1992-06-16 Pfizer Inc. Polypeptides useful as blockers of calcium channels

Also Published As

Publication number Publication date
HRP931050B1 (en) 1999-04-30
IL106424A0 (en) 1993-11-15
FI933349A (fi) 1994-01-28
JPH07504685A (ja) 1995-05-25
ZA935370B (en) 1995-01-26
GR3024637T3 (en) 1997-12-31
DE69313650T2 (de) 1998-01-08
CA2139947A1 (en) 1994-02-03
HUT67467A (en) 1995-04-28
CN1086824A (zh) 1994-05-18
ATE157672T1 (de) 1997-09-15
KR950702577A (ko) 1995-07-29
MY131356A (en) 2007-08-30
FI933349A0 (fi) 1993-07-26
ES2105284T3 (es) 1997-10-16
DE69313650D1 (en) 1997-10-09
AU4407893A (en) 1994-02-14
EP0656905A1 (en) 1995-06-14
CZ281539B6 (cs) 1996-10-16
MX9304497A (es) 1994-04-29
YU51593A (sh) 1997-01-08
RU2104286C1 (ru) 1998-02-10
BR9306796A (pt) 1998-12-08
HRP931050A2 (en) 1996-12-31
CZ9500200A3 (en) 1995-10-18
JP2571197B2 (ja) 1997-01-16
US5599559A (en) 1997-02-04
EP0656905B1 (en) 1997-09-03
RU95105340A (ru) 1996-10-27
AU662066B2 (en) 1995-08-17
HU213353B (en) 1997-05-28
NZ253611A (en) 1996-09-25
PL307258A1 (en) 1995-05-15
TW271442B (hu) 1996-03-01
HU9302158D0 (en) 1993-11-29
DK0656905T3 (da) 1997-10-20
WO1994002511A1 (en) 1994-02-03
CA2139947C (en) 1998-06-30

Similar Documents

Publication Publication Date Title
SK10395A3 (en) Polypeptide and its using
JPH09118690A (ja) 興奮性アミノ酸神経伝達物質の拮抗物質として、および／またはカルシウムチャンネルの遮断剤として有用なポリペプチド
CA2026418C (en) Polypeptides useful as blockers of calcium channels
EP0672056B1 (en) Calcium channel blocking polypeptides from filistata hibernalis
US5627154A (en) Calcium channel blocking polypeptides from Heteropoda venatoria
EP0668872B1 (en) Calcium channel blocking polypeptides from theraphosidae aphonopelma